Revenues in the third quarter of 2005 reflected lower prescription growth and increased competition in key therapeutic markets in the U.S., such as the lipid-lowering market, where the rate of growth in the third quarter declined significantly versus the first half of the year; and the erectile dysfunction market, which has been in decline compared to 2004.
- Hank McKinnell
HTML Medium Image Quote Embed:
HTML Large Image Quote Embed:
HTML Text Quote Embed with <blockquote>:
BB Forums Medium Image Quote Embed with <BB Code>:
Please login in order to submit reports.